Moxifloxacin: Clinically compatible contrast agent for multiphoton imaging

• Main Authors: Wang, Taejun (Author), Jang, Won Hyuk (Author), Lee, Seunghun (Author), Yoon, Calvin J. (Author), Lee, Jun Ho (Author), Kim, Bumju (Author), Hwang, Sekyu (Author), Hong, Chun-Pyo (Author), Yoon, Yeoreum (Author), Lee, Gilgu (Author), Le, Viet-Hoan (Author), Bok, Seoyeon (Author), Ahn, G-One (Author), Lee, Jaewook (Author), Gho, Yong Song (Author), Chung, Euiheon (Author), Kim, Sungjee (Author), Jang, Myoung Ho (Author), Myung, Seung-Jae (Author), Kim, Myoung Joon (Author), So, Peter T. C. (Contributor), Kim, Ki Hean (Author)
• Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Mechanical Engineering (Contributor)
• Format: Article
• Language: English
• Published: Springer Nature, 2017-05-26T18:23:22Z.
• Subjects: Article
• Online Access: Get fulltext

Multiphoton microscopy (MPM) is a nonlinear fluorescence microscopic technique widely used for cellular imaging of thick tissues and live animals in biological studies. However, MPM application to human tissues is limited by weak endogenous fluorescence in tissue and cytotoxicity of exogenous probes. Herein, we describe the applications of moxifloxacin, an FDA-approved antibiotic, as a cell-labeling agent for MPM. Moxifloxacin has bright intrinsic multiphoton fluorescence, good tissue penetration and high intracellular concentration. MPM with moxifloxacin was demonstrated in various cell lines, and animal tissues of cornea, skin, small intestine and bladder. Clinical application is promising since imaging based on moxifloxacin labeling could be 10 times faster than imaging based on endogenous fluorescence.
David H. Koch Institute for Integrative Cancer Research at MIT (Bridge Initiative)